Adrian Kowalczyk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adrian Kowalczyk has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Joanna Zawitkowska
Department of Pediatric Hematology, Oncology and Transplantation, Medical University of Lublin, Lublin, Poland
2 shared publications - Julia Kowalczyk
Medical University of Lublin, Poland
2 shared publications - Monika Lejman
Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, A. Gębali 6, 20-093 Lublin, Poland
2 shared publications - Agata Tokarzewska
Student Scientific Association, The Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Doktora Kazimierza Jaczewskiego 8, 20-090 Lublin, Poland
1 shared publication - Aleksander Siwek
Medical University of Lublin, Poland
1 shared publication - Balbina Tybulczuk
Medical University of Lublin, Lublin, Poland
1 shared publication
Latest Publications
- Open Access
- 30 September 2026
- Published by Medical University of Lublin in Current Issues in Pharmacy and Medical Sciences
- Vol. 39 (3) , 189-193
Severe onset of newly diagnosed secondary immune thrombocytopenia in a 4-year-old patient as a complication of HHV-7 infection – A case report
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by isolated thrombocytopenia. Viral infections are one of the most common triggers, particularly in children. However, the role of human herpesvirus 7 (HHV-7) in ITP pathogenesis has yet to be established. Here, we present the case of a previously healthy 4-year-old girl with severe hemorrhagic symptoms and a critically low platelet count of 2,000/µL. Additional laboratory tests confirmed an acute HHV-7 infection. Despite initial treatment with platelet transfusions and intravenous immunoglobulin, the patient's thrombocytopenia persisted, necessitating the introduction of glucocorticoids. The patient showed gradual clinical and hematological improvement, with complete resolution by day 19 of hospitalization. Other causes of secondary ITP, including malignancy and autoimmune diseases, were ruled out. This case suggests a possible association between HHV-7 infection and the onset of secondary ITP in children. The case underscores the importance of comprehensive viral diagnostics in pediatric patients with severe thrombocytopenia and emphasizes the need for further research on the role of HHV-7 in hematologic complications.
- 30 September 2026
- Published by Medical University of Lublin in Current Issues in Pharmacy and Medical Sciences
- Vol. 39 (3) , 189-193
Open AccessSevere onset of newly diagnosed secondary immune thrombocytopenia in a 4-year-old patient as a complication of HHV-7 infection – A case report
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by isolated thrombocytopenia. Viral infections are one of the most common triggers, particularly in children. However, the role of human herpesvirus 7 (HHV-7) in ITP pathogenesis has yet to be established. Here, we present the case of a previously healthy 4-year-old girl with severe hemorrhagic symptoms and a critically low platelet count of 2,000/µL. Additional laboratory tests confirmed an acute HHV-7 infection. Despite initial treatment with platelet transfusions and intravenous immunoglobulin, the patient's thrombocytopenia persisted, necessitating the introduction of glucocorticoids. The patient showed gradual clinical and hematological improvement, with complete resolution by day 19 of hospitalization. Other causes of secondary ITP, including malignancy and autoimmune diseases, were ruled out. This case suggests a possible association between HHV-7 infection and the onset of secondary ITP in children. The case underscores the importance of comprehensive viral diagnostics in pediatric patients with severe thrombocytopenia and emphasizes the need for further research on the role of HHV-7 in hematologic complications.
- Open Access
- 8 January 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
The use of venetoclax in the treatment of acute lymphoblastic leukemia—a systematic review
Background: The 5-year overall survival rates in acute lymphoblastic leukemia (ALL) vary depending on the patient’s age group (from 93% to under 30%). However, in the case of relapsed/refractory ALL (R/R ALL), the complete remission (CR) rate in the pediatric patient group is 44% and in the adult population—18%. Therefore, further research on new therapeutic compounds is necessary. Objectives: This systematic review aims to analyze the results of clinical studies concerning the use of venetoclax alone or in combination with other drugs in the treatment of ALL. Design: The systematic review was conducted in accordance with the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analysis. The Quality Assessment Tool for Before-After (Pre-Post) Studies With No Control Group by the National Heart, Lung, and Blood Institute was used to assess the quality of included studies. Data sources and methods: PubMed and Web of Science were used for the literature review. All clinical studies reporting outcomes in patients with ALL treated with venetoclax met the inclusion criteria. As a result of our search process for articles, a total of 989 records were obtained. After excluding records that did not meet the inclusion criteria or met the exclusion criteria, seven articles were finally obtained. Results: In seven identified clinical trials, CR rate ranged from 22% to 59.6% in patients with R/R ALL, while in the group of patients with newly diagnosed ALL, it ranged from 90.9% to 96%. The most common adverse events of grade 3 or higher were hematological complications, including neutropenia (71 episodes among 110 patients), anemia (70/141), and thrombocytopenia (70/141). Conclusion: Based on the results of phase I clinical trials, further clinical trials should be conducted to assess the therapeutic potential of venetoclax in the treatment of ALL.
- 8 January 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Open AccessThe use of venetoclax in the treatment of acute lymphoblastic leukemia—a systematic review
Background: The 5-year overall survival rates in acute lymphoblastic leukemia (ALL) vary depending on the patient’s age group (from 93% to under 30%). However, in the case of relapsed/refractory ALL (R/R ALL), the complete remission (CR) rate in the pediatric patient group is 44% and in the adult population—18%. Therefore, further research on new therapeutic compounds is necessary. Objectives: This systematic review aims to analyze the results of clinical studies concerning the use of venetoclax alone or in combination with other drugs in the treatment of ALL. Design: The systematic review was conducted in accordance with the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analysis. The Quality Assessment Tool for Before-After (Pre-Post) Studies With No Control Group by the National Heart, Lung, and Blood Institute was used to assess the quality of included studies. Data sources and methods: PubMed and Web of Science were used for the literature review. All clinical studies reporting outcomes in patients with ALL treated with venetoclax met the inclusion criteria. As a result of our search process for articles, a total of 989 records were obtained. After excluding records that did not meet the inclusion criteria or met the exclusion criteria, seven articles were finally obtained. Results: In seven identified clinical trials, CR rate ranged from 22% to 59.6% in patients with R/R ALL, while in the group of patients with newly diagnosed ALL, it ranged from 90.9% to 96%. The most common adverse events of grade 3 or higher were hematological complications, including neutropenia (71 episodes among 110 patients), anemia (70/141), and thrombocytopenia (70/141). Conclusion: Based on the results of phase I clinical trials, further clinical trials should be conducted to assess the therapeutic potential of venetoclax in the treatment of ALL.
- Open Access
- 3 May 2023
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 26 (1) , 17-26
Current strategies of the brachial plexus palsy management
The importance of brachial plexus palsy treatment is associated with its significant severity, along with Brachial plexus palsies can be treated by means of many different surgical and non-surgical methods which allow regeneration of full efficiency of the affected limb. The choice of method depends on such factors as type and region of injury, patient’s age or clinical presentation of the injury. The purpose of this review is to present current strategies of treating brachial plexus palsies, depending on therapeutic needs of the particular patient. This is a review study based upon selective literature overview, with emphasis on works published within past 13 years. 6 separate methods of brachial plexus palsy were assessed, without distinction of the reason of palsy occurring. Some of the invasive methods include operative treatment performed directly on occupied nervous tissue, such as microneural plexus reconstruction and nerve transfers (lower subscapular nerve transfer and contralateral C7 nerve transfer) whilst the others revolve around restoration of function of affected neighboring structures by themselves, e.g. shoulder tendon transfers. Rehabilitation and botulinum toxin-based treatment are non-operative methods revolving around enhancement of the function of the affected upper limb. Main measure of effectiveness of the treatment is assessment of the range of motion of the affected limb (ROM). There is still not enough information available regarding long-term efficiency of microneural plexus reconstruction and botulinum toxin-based treatment. They require further investigation while other methods are used commonly.
- 3 May 2023
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 26 (1) , 17-26
Open AccessCurrent strategies of the brachial plexus palsy management
The importance of brachial plexus palsy treatment is associated with its significant severity, along with Brachial plexus palsies can be treated by means of many different surgical and non-surgical methods which allow regeneration of full efficiency of the affected limb. The choice of method depends on such factors as type and region of injury, patient’s age or clinical presentation of the injury. The purpose of this review is to present current strategies of treating brachial plexus palsies, depending on therapeutic needs of the particular patient. This is a review study based upon selective literature overview, with emphasis on works published within past 13 years. 6 separate methods of brachial plexus palsy were assessed, without distinction of the reason of palsy occurring. Some of the invasive methods include operative treatment performed directly on occupied nervous tissue, such as microneural plexus reconstruction and nerve transfers (lower subscapular nerve transfer and contralateral C7 nerve transfer) whilst the others revolve around restoration of function of affected neighboring structures by themselves, e.g. shoulder tendon transfers. Rehabilitation and botulinum toxin-based treatment are non-operative methods revolving around enhancement of the function of the affected upper limb. Main measure of effectiveness of the treatment is assessment of the range of motion of the affected limb (ROM). There is still not enough information available regarding long-term efficiency of microneural plexus reconstruction and botulinum toxin-based treatment. They require further investigation while other methods are used commonly.